Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Codexis Appoints Patrick Yang to Board of Directors

Published: Friday, February 28, 2014
Last Updated: Friday, February 28, 2014
Bookmark and Share
Dr. Yang brings significant experience in pharmaceutical manufacturing and process development.

Codexis, Inc. has announced the appointment of Patrick Yang, Ph.D., to its board of directors. Dr. Yang brings significant experience in pharmaceutical manufacturing and process development to the Codexis board, following several executive leadership roles within the pharmaceutical industry.

John Nicols, President and CEO of Codexis, said, "Dr. Yang's impressive track record in the pharmaceuticals industry, including leadership positions at Roche, Genentech and Merck, will bring valuable experience to our board. In addition to leveraging his extensive network in the global pharmaceutical industry, Codexis expects to greatly benefit from applying Dr. Yang's broad operational and technological expertise to help accelerate the profitable growth of our biocatalyst business going forward."

Dr. Yang commented, "I am excited to join the board of Codexis, particularly at this important stage in the company's history. The pharmaceutical market is the right focus for Codexis and its great technology, and now that Codexis is fully focused on this market, I can use my 35 years of experience in this industry to create value for both the company's shareholders and customers."

Dr. Yang served most recently as Executive Vice President and Global Head of Technical Operations for F. Hoffmann-La Roche AG, a world leader in research-focused pharmaceuticals and diagnostics.

In this role, Dr. Yang was responsible for Roche's pharmaceutical and biotech manufacturing operations, process development, quality, regulatory, supply management and distribution functions, and was accountable for more than 15,000 employees worldwide.

Previously, Dr. Yang worked for Genentech, a leading biotechnology company, for about 10 years, where his most recent position was Executive Vice President of Product Operations. At Genentech, Dr. Yang was responsible for Genentech's manufacturing, process development, quality, regulatory affairs and distribution functions.

Prior to Genentech, Dr. Yang held several leadership roles at Merck & Co., including Vice President of Asia/Pacific Manufacturing Operations and Vice President of, Supply Chain Management. He also previously worked at General Electric Co. and Life Systems, Inc. Dr. Yang serves on the board of directors of Tesoro Corporation (NYSE:TSO), an independent refiner and marketer of petroleum products.

Dr. Yang earned a Bachelor of Science in Engineering from the National Chiaotung University in Taiwan, a Master of Science in Electrical Engineering from the University of Cincinnati and a Ph.D. in engineering from the Ohio State University.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
Designing Drugs with a Whole New Toolbox
Researchers develop methods to design small, targeted proteins with shapes not found in nature.
Small Molecules Lead to a Big Change in Reaction Outcomes
Scientists have changed the behaviour of a group of molecules involved in carbon-oxygen bond synthesis.
Targeting Fat to Treat Cancer
Researchers develop novel cancer treatment that halts fat synthesis in cells, stunting tumors.
Hyperstable Peptides for 'On-Demand' Drugs
These small molecules can fold into different conformations that could allow for greater flexibility in precision drug design
Drug Leads Identified to Combat Heart Disease
Using three supercomputers, researchers surveyed protein structures through accelerated molecular dynamics.
Accelerating the Path to Molecules for Medicine
Researchers convert carbon-hydrogen bonds into nitriles - converting organic molecules into components of medicines.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos